JSPR
Jasper Therapeutics, Inc.
There isn't enough reported data to score JSPR yet.
JSPR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
JSPR's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
JSPR PE Valuation
JSPR has no meaningful PE right now: it lost money over the past year.
JSPR Forward outlook
There aren't enough analyst estimates for JSPR to show an outlook.
JSPR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$177.90 | -$36.31 |
| Q2 2025 | -$181.20 | -$28.81 |
| Q1 2025 | -$158.10 | +$10.19 |
| Q4 2024 | -$146.70 | +$38.69 |
| Q3 2024 | -$141.59 | +$112.75 |
| Q2 2024 | -$152.39 | +$149.95 |
| Q1 2024 | -$168.29 | +$171.23 |
| Q4 2023 | -$185.39 | +$123.61 |
JSPR is still losing money, but less than at its worst: $177.90 per share over the past year, against $339.52 at its worst in early 2023.
JSPR Quarterly Revenue
JSPR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$14.5M | +$8.3M |
| Q4 2025 | -$21.9M | -$733K |
| Q3 2025 | -$17M | -$2.9M |
| Q2 2025 | -$15.5M | -$3.8M |
| Q1 2025 | -$22.8M | -$7.1M |
| Q4 2024 | -$21.1M | -$4.7M |
| Q3 2024 | -$14.1M | -$2.1M |
| Q2 2024 | -$11.7M | +$1.6M |
JSPR has burned cash in almost every quarter: −$69M over the past year, against −$70M the year before.
JSPR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +838 shares |
| 1 year | +91% | +456K shares |
| 3 years | +226% | +663K shares |
JSPR has 956,565 diluted shares, up 91% from a year ago.
JSPR Net Leverage
JSPR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
JSPR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 13.5 | Oversold |
JSPR's weekly RSI is 36 (neutral) and its Stochastic is 14 (oversold).
JSPR PE vs Healthcare Sector
JSPR has no meaningful PE right now: it lost money over the past year.
JSPR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.0 | 16% below |
| 20 week MA | $18.6 | 28% below |
| 50 week MA | $28.2 | 53% below |
| 100 week MA | $90.9 | 85% below |
| 200 week MA | $296.8 | 95% below |
JSPR is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
JSPR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2,946.0 | $3,027.0 | +2.7% |
| 2021 | $3,027.0 | $2,784.0 | -8% |
| 2022 | $2,784.0 | $166.2 | -94% |
| 2023 | $166.2 | $236.7 | +42% |
| 2024 | $236.7 | $667.5 | +182% |
| 2025 | $667.5 | $52.8 | -92% |
| 2026 YTD | $52.8 | $13.4 | -75% |
JSPR's yearly returns have swung widely, from +182% in 2024 to −94% in 2022. It's down 75% so far in 2026.